Cite
HARVARD Citation
Guillerey, C. et al. (2021). Systemic administration of IL‐33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. Immunology and cell biology. 99 (1), pp. 65-83. [Online].